Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Assets Average (2016 - 2026)

Cytosorbents filings provide 14 years of Assets Average readings, the most recent being $45.0 million for Q4 2025.

  • On a quarterly basis, Assets Average fell 5.51% to $45.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $45.0 million, a 5.51% decrease, with the full-year FY2025 number at $45.8 million, down 8.75% from a year prior.
  • Assets Average hit $45.0 million in Q4 2025 for Cytosorbents, down from $46.9 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $96.6 million in Q3 2021 to a low of $45.0 million in Q4 2025.
  • Median Assets Average over the past 5 years was $52.8 million (2023), compared with a mean of $63.4 million.
  • Biggest five-year swings in Assets Average: skyrocketed 147.78% in 2021 and later plummeted 32.01% in 2022.
  • Cytosorbents' Assets Average stood at $92.3 million in 2021, then tumbled by 32.01% to $62.8 million in 2022, then dropped by 19.9% to $50.3 million in 2023, then decreased by 5.33% to $47.6 million in 2024, then fell by 5.51% to $45.0 million in 2025.
  • The last three reported values for Assets Average were $45.0 million (Q4 2025), $46.9 million (Q3 2025), and $49.4 million (Q2 2025) per Business Quant data.